



# FACT SHEET

Media Contact: Ed Lang (650) 467-2313  
Investor Contact: Kathee Littrell (650) 225-1034  
Advocacy Contact: Kristin Reed (650) 467-9831

## Commitment to Patient Access

Genentech is committed to making sure price is not a barrier to access for patients. The vast majority of patients who receive treatment with Genentech medicines have insurance that covers the cost of their treatment. Genentech supports several programs for eligible patients treated in the United States who do not have insurance, cannot afford their out-of-pocket co-pay costs or need assistance with health insurance coverage or reimbursement issues through the Genentech Access Solutions program.

- Since 1985, when our first product was approved, Genentech has donated approximately \$1 billion in free medicine to uninsured patients through the [Genentech® Access to Care Foundation \(GATCF\)](#) and other charitable programs.
- The company recently expanded GATCF to provide free drug to eligible patients who have private insurance and have met or exceeded their lifetime maximum benefits.
- In February 2007, the company announced the expansion of GATCF to help address the needs of financially eligible patients enrolled in a Medicare Part D plan who are prescribed Tarceva® (erlotinib).

### Avastin Patient Assistance Program

The Avastin Patient Assistance program provides an opportunity for physicians and eligible patients who are treated for an FDA-approved indication and who reach an annual dosage of 10,000 mg to receive free Avastin from Genentech for the remainder of the 12-month period.

This program is open to all patients receiving Avastin regardless of insurance coverage. To be eligible for the program, patients will need to:

- Receive 10,000 mg of Avastin for a FDA-approved indication in a twelve-month period.
- Earn less than \$100,000 adjusted gross income per year.
- Receive the 10,000 mg of Avastin from a single provider or provider organization.

For more information, please call (866) 4 ACCESS or visit [www.GenentechAccessSolutions.com](http://www.GenentechAccessSolutions.com).

### **Co-Pay Assistance**

Since 2005, Genentech has donated more than \$140 million to independent non-profit organizations that provide co-pay assistance. To learn more about these independent, public charities, patients can speak with a specialist from Genentech's Access Solutions group by calling (866) 4 ACCESS or visiting [www.GenentechAccessSolutions.com](http://www.GenentechAccessSolutions.com).

### **Genentech Access Solutions**

Genentech's Access Solutions provides one-stop access to a broad array of coverage, reimbursement and patient assistance services. For more information on potential assistance options, please call (866) 4 ACCESS or visit [www.GenentechAccessSolutions.com](http://www.GenentechAccessSolutions.com).

### **Avastin Indications and Safety Information**

#### ***Indications***

Avastin, in combination with intravenous 5-fluorouracil-based chemotherapy, is indicated for first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum.

Avastin, in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer.

#### ***Boxed WARNINGS and Additional Important Safety Information***

The most serious adverse events associate with Avastin across all trials were **GI perforation, wound healing complication, hemorrhage**, arterial thromboembolic events, hypertensive crisis, reversible posterior leukoencephalopathy syndrome, neutropenia and infection, nephrotic syndrome, and congestive heart failure. The most common adverse events seen in patients receiving Avastin across all studies were asthenia, pain, abdominal pain, headache, hypertension, diarrhea, nausea, vomiting, anorexia, stomatitis, constipation, upper respiratory infection, epistaxis, dyspnea, exfoliative dermatitis, and proteinuria.

# # #